잠시만 기다려 주세요. 로딩중입니다.

Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex: a subanalysis from the BENEFIT-KOREA study

Clinical Hypertension 2021년 27권 1호 p.9 ~ 9
조경임, 전동운, 안효승, 진동규, 이현상, 이종영, 임홍석, Manolis Athanasios J., 나승운, 박상원,
소속 상세정보
조경임 ( Cho Kyoung-Im ) - Kosin University Gospel Hospital Department of Internal Medicine Division of Cardiology
전동운 ( Jeon Dong-Woon ) - National Health Insurance Service Ilsan Hospital Department of Internal Medicine
안효승 ( Ahn Hyo-Seung ) - Sahmyook Medical Center Department of Internal Medicine Division of Cardiology
진동규 ( Jin Dong-Kyu ) - Soonchunhyang University Cheonan Hospital Department of Internal Medicine
이현상 ( Lee Hyun-Sang ) - CHA Gumi Medical Center Department of Cardiology
이종영 ( Lee Jong-Young ) - Sungkyunkwan University School of Medicine Kangbuk Samsung Hospital Department of Internal Medicine
임홍석 ( Lim Hong-Seok ) - Ajou University School of Medicine Department of Cardiology
 ( Manolis Athanasios J. ) - Greece Asklepeion General Hospital Department of Cardiology
나승운 ( Rha Seung-Woon ) - Korea University Guro Hospital Cardiovascular Center
박상원 ( Park Sang-Won ) - A. Menarini Korea Ltd.

Abstract


Background: BENEFIT-KOREA (BEnefits after 24?weeks of NEbivolol administration For essential hypertensIon patients wiTh various comorbidities and treatment environments in Korea) study, an observational study in South Korea, demonstrated the efficacy and safety of nebivolol in Asian patients with essential hypertension with and without comorbidities in real-world settings. We present a subanalysis of the efficacy and safety of nebivolol across age and sex in the BENEFIT-KOREA cohort.

Methods: Adult South Korean patients with essential hypertension participated in the prospective, single-arm, open, observational BENEFIT-KOREA study; 3011 patients received nebivolol as monotherapy or add-on therapy. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), and pulse rate at 12 and 24?weeks were evaluated. Participants were divided into three age groups?young males and females:
Results: The mean age of study participants was 63.5?±?12.9?years; majority were between 50 and 69?years of age and 40.4% were females. A significant decrease was observed in mean SBP, DBP, and pulse rate from baseline at 12 and 24?weeks in males and females across all age groups analyzed (all P?
Conclusions: Our subanalysis from the real-world BENEFIT-KOREA study in Asian patients with essential hypertension demonstrated the efficacy and safety of once-daily nebivolol across age groups with no between-sex differences.

키워드

Essential hypertension; Nebivolol; Asian; Monotherapy; Combination therapy; Add-on therapy; Age; Sex

원문 및 링크아웃 정보

등재저널 정보